Janssen's MS pill outshines Sanofi's Aubagio in phase 3 tria...

Johnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio pill in adults with relapsing multiple sclerosis.

Who will be the biggest pharma players in orphan drugs?

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.

Mylan’s Lantus biosimilar held up by manufacturing issue

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9...

Sanofi's eczema drug gets EU approval to treat adolescents

The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron's eczema drug Dupixent (dupilumab) to include adolescents, while new phase 3

Almirall gets in on the eczema action

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.